蕈样肉芽肿或Sézary综合征治疗中莫格利珠单抗相关皮疹的临床特征
该回顾性病例系列纳入2013至2020年间在一家大型学术转诊中心接受莫格利珠单抗治疗的19例MF或SS患者,均出现经临床病理与分子检测确认为药疹的皮疹。MAR中位起病时间为119天,主要有4种临床表现,最常见累及头颈部,组织病理表现多样;多数患者停药但无危及生命的严重皮肤不良反应,4例再次用药未见危及生命事件。
要点
- MAR起病延迟,中位119天,临床可呈4种表现,易与疾病复发或进展混淆。
- 皮疹好发于头颈部(含头皮),组织病理多样,需结合免疫组化与T细胞克隆性检测鉴别。
- 出现MAR并非必须永久停用莫格利珠单抗,部分患者可再次用药。
核心结论
- 莫格利珠单抗相关皮疹临床表现异质、起病延迟,好发于头颈部,临床上难以与疾病复发或进展区分。
- 识别常见临床表现有助于避免不必要地停用莫格利珠单抗。
- 出现MAR并不必然需要永久停用或避免再次使用莫格利珠单抗。
研究设计与样本
- 回顾性病例系列,来自一家大型学术转诊中心的多学科皮肤淋巴瘤门诊与肿瘤皮肤科支持门诊。
- 纳入2013年1月1日至2020年1月1日期间接受莫格利珠单抗治疗、诊断为MF或SS且出现新发或加重皮疹的患者,共19例。
- 皮疹经临床病理联系判定为药疹,并以分子检测排除活动性恶性疾病。
- 患者中位年龄65岁(范围38-82岁),男性10例(52.6%)。
主要发现
- MAR中位起病时间为119天(范围56天至3.8年)。
- MAR有4种主要临床表现:伴脱发的毛囊性MF样头皮斑块、丘疹和/或斑块、光加重性皮炎、麻疹样或红皮病样皮炎。
- 最常累及的头颈部解剖区域包括头皮。
- 组织病理表现多样,与主要临床形态学表现不相对应。
- 免疫组化与T细胞克隆性辅助检测有助于区分MAR与疾病。
关键数值与推荐
- 19例MAR患者中14例停用莫格利珠单抗,但未发生危及生命的严重皮肤不良反应,停药决定通常为多因素。
- 4例患者再次接受莫格利珠单抗治疗,未发生危及生命的药物相关事件。
- MAR的处理方法包括外用糖皮质激素、全身糖皮质激素和/或甲氨蝶呤。
临床怎么用
- 对MF或SS患者使用莫格利珠单抗期间出现新发或加重皮疹时,应结合临床病理与分子检测鉴别MAR与疾病复发或进展。
- 认识MAR的4种常见临床表现可减少因误判而 unnecessarily 停药。
- 出现MAR后可根据情况采用外用糖皮质激素、全身糖皮质激素和/或甲氨蝶呤处理,并非一律永久停药。
局限性
- 为单中心回顾性病例系列,样本量19例。
- 原文未报告对照人群及长期随访结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Mogamulizumab is a monoclonal antibody against CCR4 approved for treatment for mycosis fungoides (MF) and Sézary syndrome (SS). Mogamulizumab-associated rash (MAR) is difficult to differentiate from cutaneous MF or SS, which can lead to unnecessary discontinuation of drug use because of concern for severe drug reaction or incorrect presumption of disease relapse or progression in the skin. OBJECTIVE: To examine the most common clinical presentations of MAR in patients with MF or SS and the diagnostic and management challenges. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case series assessed patients from a multidisciplinary cutaneous lymphoma clinic and supportive oncodermatology clinic at a major academic referral center who had a diagnosis of MF or SS and received mogamulizumab from January 1, 2013, to January 1, 2020. Treatment was followed by new or worsening rash with skin biopsy results compatible with drug eruption determined by clinicopathologic correlation and molecular testing to exclude active malignant disease. EXPOSURES: At least 1 dose of mogamulizumab. MAIN OUTCOMES AND MEASURES: Mogamulizumab-associated rash was characterized by clinical features, including time to onset, clinical presentation, histopathologic features, and management approach. RESULTS: The study included 19 patients with MF or SS who developed MAR (median age, 65 years; age range, 38-82 years; 10 [52.6%] male). Median time to MAR onset was 119 days (range, 56 days to 3.8 years). Patients with MAR exhibited 4 predominant clinical presentations: (1) folliculotropic MF-like scalp plaques with alopecia, (2) papules and/or plaques, (3) photoaccentuated dermatitis, and (4) morbilliform or erythrodermic dermatitis. The most common anatomical region involved was the head and neck, including the scalp. Histopathologic findings were variable and did not correspond to primary clinical morphologic findings. Immunohistochemistry and T-cell clonality ancillary testing were helpful to distinguish MAR from disease. Most patients with MAR (14 of 19) discontinued mogamulizumab treatment; however, no life-threatening severe cutaneous adverse drug reactions occurred, and the decision for drug therapy cessation was usually multifactorial. Four patients were treated again with mogamulizumab with no life-threatening drug-related events. Approaches to management of MAR include topical corticosteroids, systemic corticosteroids, and/or methotrexate. CONCLUSIONS AND RELEVANCE: This case series found that mogamulizumab-associated rash had a heterogeneous clinical presentation with variable and delayed onset in patients with MF or SS. Mogamulizumab-associated rash exhibited a predilection for the head and neck and was difficult to clinically distinguish from relapse or progression of disease. Recognition of the most common clinical presentations can help prevent unnecessary discontinuation of mogamulizumab treatment. The presence of MAR does not necessitate permanent discontinuation of or avoidance of retreatment with mogamulizumab.
引用
- Hirotsu KE, Neal TM, Khodadoust MS, et al. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome. JAMA Dermatol. 2021. PMID: 33881447. doi:10.1001/jamadermatol.2021.0877
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。